NewslettersHematopoiesis NewsFDA Approves Inotuzumab Ozogamicin for Pediatric CD22+ B-Cell Precursor Acute Lymphoblastic LeukemiaBy lbeveridge - March 11, 2024042The FDA has approved inotuzumab ozogamicin for the treatment of pediatric patients aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.[OncLive]Press Release